Not admitted · Third-party claim
Rules 1.1.0 · as of 14 Sep 2026
Owen Scott Muir · Said 4 Nov 2025 · owen-1942
Quote
Third-party claim
“This is why Janssen, the manufacturer, is still making huge profits from a simple enantiomer—on track for $2b this year.”
Guest section by a reader, 'Dr. MS', a psychiatrist with bipolar disorder, analyzing the KARMA-Dep 2 ketamine vs midazolam trial (JAMA Psychiatry). He argues IV ketamine beats intranasal esketamine but is generic, so Janssen keeps profiting from Spravato, which he says is on track for $2 billion in sales in 2025.
A quoted or paraphrased claim by someone else that the author does not adopt as their own.